Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its epimers

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal form of cancer with limited treatment options and poor survival rates. Cannabinoids have demonstrated antiproliferative and proapoptotic effects in various cancer types, including PDAC, making them promising therapeutic agents. However, clinical efficacy remains underexplored, particularly for cannabinoids like cannabidiol and tetrahydrocannabinol, which show limited activity against pancreatic cancer. Materials and methods: We synthesized novel cannabinoid analogues, including CCL-106 and its epimers CCL-114 and CCL-115, which exhibit superior antitumor activity